Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026
Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026
1700 Owens Street, Suite 595
San Francisco, CA 94158
1200 Westlake Ave N, Suite 900
Seattle, WA 98109
© 2025 venBio. All Rights Reserved.